RESUMEN
Phototherapy is a safe and effective treatment for many dermatologic conditions. With the advent of novel biologics and small molecule inhibitors, it is important to critically evaluate the role of phototherapy in dermatology. Surveys have shown that many dermatology residency programs do not dedicate time to teaching residents how to prescribe or administer phototherapy. Limitations of phototherapy include access to a center, time required for treatments, and insurance approval. Home phototherapy, a viable option, is also underused. However, it should be emphasized that modern phototherapy has been in use for over 40 years, has an excellent safety profile, and does not require laboratory monitoring. It can be safely combined with many other treatment modalities, including biologics and small molecule inhibitors. In addition, phototherapy costs significantly less than these novel agents. Dermatologists are the only group of physicians who have the expertise and proper training to deliver this treatment modality to our patients. Therefore, to continue to deliver high-quality, cost-effective care, it is imperative that phototherapy be maintained as an integral part of the dermatology treatment armamentarium.
Asunto(s)
Factores Biológicos/uso terapéutico , Dermatología/tendencias , Fototerapia/tendencias , Pautas de la Práctica en Medicina/tendencias , Enfermedades de la Piel/tratamiento farmacológico , Factores Biológicos/economía , Análisis Costo-Beneficio , Dermatología/economía , Dermatología/historia , Dermatología/métodos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Fototerapia/efectos adversos , Fototerapia/economía , Fototerapia/historia , Pautas de la Práctica en Medicina/economía , Pautas de la Práctica en Medicina/historia , Enfermedades de la Piel/economía , Resultado del TratamientoRESUMEN
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients' growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.
Asunto(s)
Hidradenitis Supurativa/diagnóstico , Hidradenitis Supurativa/terapia , Femenino , Humanos , Masculino , Estudios Prospectivos , Calidad de Vida , Reproducibilidad de los ResultadosRESUMEN
Hidradenitis suppurativa is a chronic inflammatory skin disease characterized by inflammatory nodules, abscesses, and sinus tracts in intertriginous areas that has a significant impact on patient quality of life. Treatments range from topical, intralesional, systemic, and surgical. Furthermore, laser and light-based treatment options have become increasingly popular because of the limitations of adverse effects associated with systemic therapy and decreased down-time associated with laser and light therapy. These modalities are thought to work through a variety of mechanisms including decreasing inflammation, destroying hair follicles, targeting sebaceous glands, killing bacteria, and debulking lesions through ablation. This review explores these laser and light-based treatment modalities for the treatment of hidradenitis suppurativa.
Asunto(s)
Hidradenitis Supurativa/terapia , Terapia por Láser , Fotoquimioterapia , Humanos , Tratamiento de Luz Pulsada Intensa , Microondas/uso terapéutico , Terapia por RadiofrecuenciaAsunto(s)
Antimetabolitos Antineoplásicos/administración & dosificación , Carcinoma Basocelular/tratamiento farmacológico , Fluorouracilo/administración & dosificación , Melanoma/tratamiento farmacológico , Neoplasias Primarias Secundarias/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Administración Cutánea , Anciano de 80 o más Años , Antineoplásicos Alquilantes/efectos adversos , Carcinoma Basocelular/inducido químicamente , Quimioterapia Adyuvante , Quimioterapia del Cáncer por Perfusión Regional/efectos adversos , Humanos , Masculino , Mecloretamina/efectos adversos , Melanoma/cirugía , Neoplasias Primarias Secundarias/inducido químicamente , Neoplasias Cutáneas/inducido químicamenteRESUMEN
Pigmentary disorders are common and can be very distressing to patients. There is a need for better, standardized therapies. The authors review the most recent data for topical, systemic, light, and laser treatments for vitiligo, melasma, and postinflammatory hyperpigmentation. There is a paucity of large-scale, well-designed, randomized, controlled trials for these treatments. Treatment options are often drawn from smaller trials and case series. The treatments described in this article are promising candidates for larger follow-up studies.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Inhibidores de las Cinasas Janus/uso terapéutico , Trastornos de la Pigmentación/terapia , Antifibrinolíticos/uso terapéutico , Bimatoprost/uso terapéutico , Humanos , Hidroquinonas/uso terapéutico , Inflamación , Queratinocitos/trasplante , Láseres de Estado Sólido/uso terapéutico , Terapia por Luz de Baja Intensidad , Melanocitos/trasplante , Melanosis , Preparaciones para Aclaramiento de la Piel/uso terapéutico , Protectores Solares/uso terapéutico , Ácido Tranexámico/uso terapéutico , Vitíligo/terapia , alfa-MSH/análogos & derivados , alfa-MSH/uso terapéuticoRESUMEN
Solar urticaria (SU) is an uncommon photodermatosis that presents with sensitivity to ultraviolet (UV) or visible light which triggers urticarial lesions. Treatment of SU is a challenge and usually involves antihistamines and photoprotection as a first-line treatment. Phototherapy regimens are recommended if these first-line treatments fail to control the disease. Induction of tolerance by phototherapy (UV hardening) has been commonly described as a treatment modality. UVA1 has deeper penetration to the dermis than UVA or NB-UVB; its use in SU has not been previously reported. We present 3 patients with SU who were successfully treated with UVA1.